Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FertyBiotic Mujer Plus
- Development stage
- Unknown
- Lead developer
- Fertypharm
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
FertyBiotic Mujer Plus (also known as FertyBiotic Woman Plus) is a multi-ingredient probiotic-based dietary supplement developed by Fertypharm. It is designed to support female fertility and reproductive health, specifically in women with Polycystic Ovary Syndrome (PCOS). The formulation combines three probiotic strains (Lactobacillus rhamnosus, Lactobacillus crispatus, and Lactobacillus plantarum) intended to modulate the vaginal and endometrial microbiota with nutritional components including myo-inositol, D-chiro-inositol, melatonin, folic acid, Vitamin D3, and selenium. These ingredients work synergistically to address insulin resistance, oxidative stress, and hormonal imbalances, thereby improving oocyte quality and reproductive outcomes in both natural conception and assisted reproduction processes.
- Brand names
- FertyBiotic Mujer PlusFertyBiotic Woman Plus
- Other names
- Fertybiotic Mujer Plus
02
Targets
FOLR1 (FRα)MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on FertyBiotic Mujer Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FertyBiotic Mujer Plus.